Assenagon Asset Management S.A. Lowers Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Assenagon Asset Management S.A. cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report) by 8.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 36,484 shares of the medical equipment provider’s stock after selling 3,220 shares during the quarter. Assenagon Asset Management S.A. owned 0.05% of Lantheus worth $2,262,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of LNTH. Tucker Asset Management LLC raised its stake in shares of Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares during the last quarter. First Horizon Advisors Inc. raised its stake in shares of Lantheus by 97.0% in the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 225 shares during the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Lantheus by 60.2% in the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 160 shares during the last quarter. Covestor Ltd raised its stake in shares of Lantheus by 62.7% in the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 203 shares during the last quarter. Finally, NBC Securities Inc. purchased a new stake in shares of Lantheus during the third quarter valued at approximately $46,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of recent analyst reports. William Blair lowered Lantheus from an “outperform” rating to a “market perform” rating in a report on Monday, December 18th. B. Riley dropped their price target on Lantheus from $113.00 to $95.00 and set a “buy” rating on the stock in a report on Wednesday, January 10th. TheStreet lowered Lantheus from a “b-” rating to a “c” rating in a report on Monday, December 18th. JMP Securities reiterated a “market outperform” rating and set a $100.00 price target on shares of Lantheus in a report on Friday, February 23rd. Finally, StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.14.

Get Our Latest Stock Report on LNTH

Lantheus Stock Up 0.5 %

Shares of NASDAQ LNTH opened at $59.19 on Thursday. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $100.85. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.80 and a quick ratio of 5.45. The business’s fifty day moving average price is $59.10 and its 200-day moving average price is $63.27. The stock has a market capitalization of $4.06 billion, a PE ratio of 12.76 and a beta of 0.53.

Lantheus (NASDAQ:LNTHGet Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The firm had revenue of $354.00 million for the quarter, compared to analysts’ expectations of $350.44 million. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 5.72 EPS for the current year.

Insider Activity at Lantheus

In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the purchase, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the purchase, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. In the last three months, insiders have sold 94,545 shares of company stock worth $6,168,153. 2.10% of the stock is owned by company insiders.

About Lantheus

(Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Read More

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.